News Releases

News Releases

Date Title
Nov 7, 2022 Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update
Sesen Bio announced proposed merger with Carisma Therapeutics Combined company will focus on the advancement of Carisma’s development of engineered macrophages for the treatment of cancer and other serious disorders Transaction is expected to close in the next two to three months, subject to Sesen
Sep 21, 2022 Sesen Bio and Carisma Therapeutics Announce Merger Agreement
Transaction to create a well-funded, clinical-stage biotechnology company advancing engineered macrophages for the treatment of cancer and other serious disorders Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securities at close, including $30
Aug 8, 2022 Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update
  Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value Strong balance sheet of $161 million in cash, cash equivalents and marketable securities as of June 30, 2022 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug.
Jul 18, 2022 Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
Company intends to seek a partner for further development of Vicineum Sesen Bio continues to focus on the assessment of potential strategic alternatives CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 18, 2022-- Sesen Bio (Nasdaq: SESN ) today announced that it has made the strategic decision to
May 9, 2022 Sesen Bio Reports First Quarter 2022 Financial Results and Business Update
Strong balance sheet of $170 million in cash and cash equivalents as of March 31, 2022 , expected to fund current operating plan into the fourth quarter of 2024 CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion
May 3, 2022 Sesen Bio Provides Strategic Update
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of
Feb 28, 2022 Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
Participated in productive CMC and Clinical Type A Meetings with the FDA in the fourth quarter Type C Meeting with the FDA planned for March 28, 2022 Strong balance sheet with $163M in cash and cash equivalents as of December 31, 2021 expected to fund current operating plan into 2024 CAMBRIDGE,
Jan 10, 2022 Sesen Bio Further Enhances Team with Key Hires
Minori Rosales , M.D., Ph.D. Brings Over 15 Years of Clinical Experience Stephanie Vigue to Support Company’s Mission with Broad Corporate Finance Expertise CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 10, 2022-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein
Top